Pasritamig

N/A

Report date: 2026/05/12 20:00:17
First In Class

Base Information

Drug NamePasritamig
Drug Alias NameJNJ-78278343JNJ-8343
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionKallikrein 2 inhibitorsT cell surface glycoprotein CD3 modulators
TargetsKallikrein 2T cell surface glycoprotein CD3
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[19] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesJanssen Research & Development LlcZymeworks Inc
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdCilag AgJanssen Research & Development Llc
Inactive CompaniesN/A
Active IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A